Havranek B, Lindsey G, Higuchi Y, Itoh Y, Suzuki T, Okamoto T, et al. A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo. Commun Biol. 2023;6:513 pubmed publisher

Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2022;: pubmed publisher

Glazkova D, Bogoslovskaya E, Urusov F, Kartashova N, Glubokova E, Gracheva A, et al. Generation of SARS-CoV-2 Mouse Model by Transient Expression of the Human ACE2 Gene Mediated by Intranasal Administration of AAV-hACE2. Mol Biol. 2022;56:705-712 pubmed publisher

Zhang L, Narayanan K, Cooper L, Chan K, Skeeters S, Devlin C, et al. An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV-2. EMBO Mol Med. 2022;14:e16109 pubmed publisher

Zhang L, Narayanan K, Cooper L, Chan K, Devlin C, Aguhob A, et al. An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2. bioRxiv. 2022;: pubmed publisher

Zhang L, Dutta S, Xiong S, Chan M, Chan K, Fan T, et al. Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants. Nat Chem Biol. 2022;18:342-351 pubmed publisher

Zhang L, Dutta S, Xiong S, Chan M, Chan K, Fan T, et al. Engineered High-Affinity ACE2 Peptide Mitigates ARDS and Death Induced by Multiple SARS-CoV-2 Variants. bioRxiv. 2021;: pubmed publisher

Havranek B, Chan K, Wu A, Procko E, Islam S. Computationally Designed ACE2 Decoy Receptor Binds SARS-CoV-2 Spike (S) Protein with Tight Nanomolar Affinity. J Chem Inf Model. 2021;61:4656-4669 pubmed publisher

Chan K, Dorosky D, Sharma P, Abbasi S, Dye J, Kranz D, et al. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science. 2020;369:1261-1265 pubmed publisher